These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 31368043

  • 1. Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.
    Usman F, Nopparat J, Javed I, Srichana T.
    Drug Deliv Transl Res; 2020 Feb; 10(1):59-69. PubMed ID: 31368043
    [Abstract] [Full Text] [Related]

  • 2. Bioactivity, Safety, and Efficacy of Amphotericin B Nanomicellar Aerosols Using Sodium Deoxycholate Sulfate as the Lipid Carrier.
    Usman F, Khalil R, Ul-Haq Z, Nakpheng T, Srichana T.
    AAPS PharmSciTech; 2018 Jul; 19(5):2077-2086. PubMed ID: 29691753
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
    Gangadhar KN, Adhikari K, Srichana T.
    Int J Pharm; 2014 Aug 25; 471(1-2):430-8. PubMed ID: 24907597
    [Abstract] [Full Text] [Related]

  • 4. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data.
    Kagan L, Gershkovich P, Wasan KM, Mager DE.
    AAPS J; 2011 Jun 25; 13(2):255-64. PubMed ID: 21431453
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice.
    Saxena S, Ghosh PC.
    Pharm Res; 2000 Oct 25; 17(10):1236-42. PubMed ID: 11145229
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774.
    Chéron M, Petit C, Bolard J, Gaboriau F.
    J Antimicrob Chemother; 2003 Dec 25; 52(6):904-10. PubMed ID: 14613963
    [Abstract] [Full Text] [Related]

  • 10. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
    Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ.
    Antimicrob Agents Chemother; 2002 Mar 25; 46(3):834-40. PubMed ID: 11850269
    [Abstract] [Full Text] [Related]

  • 11. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
    Ramaswamy M, Peteherych KD, Kennedy AL, Wasan KM.
    Antimicrob Agents Chemother; 2001 Apr 25; 45(4):1184-91. PubMed ID: 11257033
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of a poly-aggregated formulation of amphotericin B in treating systemic sporotrichosis caused by Sporothrix brasiliensis.
    Ishida K, Castro RA, Torrado JJ, Serrano DR, Borba-Santos LP, Quintella LP, de Souza W, Rozental S, Lopes-Bezerra LM.
    Med Mycol; 2018 Apr 01; 56(3):288-296. PubMed ID: 28575449
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.
    Lestner JM, Howard SJ, Goodwin J, Gregson L, Majithiya J, Walsh TJ, Jensen GM, Hope WW.
    Antimicrob Agents Chemother; 2010 Aug 01; 54(8):3432-41. PubMed ID: 20439615
    [Abstract] [Full Text] [Related]

  • 15. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
    Kaur K, Kumar P, Kush P.
    Biomed Pharmacother; 2020 Aug 01; 128():110297. PubMed ID: 32480227
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.
    Risovic V, Boyd M, Choo E, Wasan KM.
    Antimicrob Agents Chemother; 2003 Oct 01; 47(10):3339-42. PubMed ID: 14506053
    [Abstract] [Full Text] [Related]

  • 19. Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles.
    Moraes Moreira Carraro TC, Altmeyer C, Maissar Khalil N, Mara Mainardes R.
    J Mycol Med; 2017 Dec 01; 27(4):519-529. PubMed ID: 28797532
    [Abstract] [Full Text] [Related]

  • 20. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
    Jung SH, Lim DH, Jung SH, Lee JE, Jeong KS, Seong H, Shin BC.
    Eur J Pharm Sci; 2009 Jun 28; 37(3-4):313-20. PubMed ID: 19491021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.